Please login to the form below

Not currently logged in
Email:
Password:

European recommendation for Galvus' monotherapy license

CHMP issues positive opinion for Novartis' diabetes drug

Novartis has won backing from European regulatory advisers for a monotherapy licence for its type II diabetes drug Galvus (vildagliptin).

This would allow the drug to be used on its own in patients whose diabetes is inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on extending the drug's current licence as a dual oral therapy.

At the moment it can only be used in combination with metformin, a sulphonylurea (if metform is inappropriate) or a thiazolidinedione in patients with insufficient glycaemic control.

CHMP positive opinions are normally passed as full European approval within three months, and would give a further boost to Galvus, which is also marketed in Europe under the brand names Jalra and Xiliarx.

The diabetes drug recently extended its licence in Europe, winning approval to treat type two diabetic patients with either moderate or severe renal impairment.

19th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics